The Latest Cannabis Articles from Streetwise Reports


Tilray Shares Fly High on Strong Q4 and FY Revenue Growth

  ()
Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition. read more >

Cannabis Market Delivering for Consumers and Investors

  ()
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value. read more >

US Cannabis Sales Hold Strong as Industry Lays Out New Lobbying Efforts to Expedite Federal Reform

Contributed Research
  ()
McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when." read more >

Tilray Shares Climb Higher on Roll Out of New Medical Cannabis Brand Symbios

  ()
Tilray Inc. shares traded 11% higher after the company reported the launch of a new medical cannabis brand, Symbios, designed to provide medicinal users with a broader spectrum of formats and cannabinoid potencies at improved price points. read more >

Investor Campbell Becher's Three Core Assets

  ()
The former Bay Street investment banker is finding himself going narrower and deeper. read more >

U.S. Cannabis Company 'Cashed Up with Catalysts Materializing'

Research Report
  ()
The many reasons why Columbia Care is 'due for a catch-up trade' are discussed in an Echelon Capital Markets report. read more >

A Message from Dr. Copper; Copper Use Is Everywhere

Contributed Opinion
  ()
Sector expert Michael Ballanger examines the rise of copper and what that rise means—and portends—for other markets, including the precious metals. read more >
Showing Results: 1 to 7 of 7

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts